Scientists Are Harvesting Stem Cells From Aborted Embryos - Are Doctors Playing God?

SCIENCE

Debbie Edwards

5/29/20263 min read

Stem cell research stands as one of the most promising frontiers in modern medicine. It offers potential treatments for conditions once considered incurable, such as Parkinson's disease, spinal cord injuries, diabetes, and heart failure. Cloning, often intertwined with stem cell discussions, particularly through techniques like somatic cell nuclear transfer, raises distinct scientific and ethical questions.

Sources of Stem Cells: Key Distinctions

Stem cells can come from multiple sources:

  • Embryonic stem cells: Derived from early-stage embryos, often leftover from IVF procedures. This process destroys the embryo, raising significant ethical concerns for those who view the embryo as having moral status.

  • Fetal tissue from abortions: Historically, human fetal tissue from elective abortions has been used in some biomedical research, including studies on human development, vaccine production (via established cell lines from the 1960s), and certain stem cell-related work. Such tissue was obtained after induced abortions, typically after the ninth week of pregnancy.

  • Placental and umbilical cord stem cells: These are collected from the placenta and umbilical cord after a live birth. Placental-derived mesenchymal stem cells (PDMSCs) offer a non-controversial, ethically unproblematic source. They show promise in regenerative applications due to their proliferative capacity and lower immunogenicity.

  • Adult and induced pluripotent stem cells (iPSCs): Reprogrammed from adult cells, avoiding embryo or fetal destruction.

  • Deceased donors: Stem cells, particularly hematopoietic stem cells from bone marrow in the vertebral column, can be recovered from consenting organ donors after death. This provides an expanding alternative supply.

Ongoing Studies and Recent Breakthroughs

Research has accelerated with iPSC advancements and organoid models. In 2025, several iPSC-based therapies received FDA Investigational New Drug (IND) clearances for Parkinson's disease, spinal cord injury, and amyotrophic lateral sclerosis (ALS).

Notable developments include:

  • Phase I/II trials using iPSC-derived dopaminergic progenitors for Parkinson's, showing motor function improvements and good safety profiles in early 2025-2026 data.

  • A 2025 study in China using chemically induced iPSCs to restore glycemic control in a Type 1 diabetes patient.

  • Japanese research transplanting iPSC-derived corneal epithelial cell sheets, improving vision in patients with limbal stem cell deficiency over two years.

  • Heart patches derived from stem cells implanted in heart failure patients, demonstrating thickened heart walls and improved ejection fraction in preliminary 2026 results.

Clinical trials also target Alzheimer's, autism, Duchenne muscular dystrophy, and graft-versus-host disease. The International Society for Stem Cell Research (ISSCR) reported 115 approved trials worldwide for 83 human pluripotent stem cell products as of late 2024, with many focusing on eye diseases, neurological disorders, and cancer.

Laws and Regulations

Regulations vary significantly by country and focus on balancing innovation with safety and ethics.

United States: No comprehensive federal ban on human cloning exists, but federal funding restrictions apply to certain embryo research under the Dickey-Wicker Amendment. The FDA regulates stem cell products as biologics, requiring rigorous approval for clinical use. Many states prohibit reproductive cloning, with some allowing therapeutic approaches. In 2025, New York proposed the Human Cloning Prohibition Act.

The ISSCR provides international guidelines updated in 2025, emphasizing ethical oversight, the 14-day rule for embryo research, and prohibitions on reproductive cloning.

International Frameworks: Many nations prohibit reproductive cloning. The United Kingdom allows therapeutic cloning under strict licensing. China bans implantation of edited or cloned embryos while permitting regulated research. Australia and parts of Europe maintain tight controls on embryo research.

Queensland, Australia, reviewed its Research Involving Human Embryos and Prohibition of Human Cloning Regulation in 2025.

Regulatory bodies stress good manufacturing practices, informed consent, and independent ethics review for clinical translation.

Future Outlook

As of mid-2026, stem cell research continues rapid advancement, driven by iPSC technology and gene editing synergies. While challenges in scaling, safety, and ethics persist, regulated progress offers hope for transformative therapies. Policymakers and scientists must collaborate to ensure responsible development that prioritizes patient safety and equitable access.

Ongoing dialogue through organizations like the ISSCR remains essential for navigating the complex intersection of science, ethics, and law.

References (selected, with dates where available):

  • DVC Stem. "Stem Cell Research: The Future of Regenerative Medicine." Updated April 15, 2026.

  • REPROCELL. "Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025." Published September 2, 2025.

  • ASBMB Today. "A new kind of stem cell is revolutionizing regenerative medicine." April 1, 2025.

  • Nature. "Don't rush promising stem-cell therapies." April 16, 2025.

  • Wikipedia and various sources on human cloning laws (ongoing as of 2026).

  • ISSCR Guidelines. August 2025 update.